Kenya - English - Pharmacy and Poisons Board

abbott laboratories s.a. (pty) ltd 219 golf club terrace constantia kloof , - clarithromycin - film-coated tablet - 250mg - antibacterials for systemic use: macrolides

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dasatinib 100mg;   - film coated tablet - 100 mg - active: dasatinib 100mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dasatinib 20mg;   - film coated tablet - 20 mg - active: dasatinib 20mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dasatinib 50mg;   - film coated tablet - 50 mg - active: dasatinib 50mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase

New Zealand - English - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - dasatinib 70mg;   - film coated tablet - 70 mg - active: dasatinib 70mg   excipient: croscarmellose sodium hyprolose lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-1-18177-a - · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with newly diagnosed chronic myeloid leukaemia (cml). · sprycel® (dasatinib) is indicated for the treatment of adults aged 18 years or over with chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. · sprycel® (dasatinib) is indicated for the treatment of paediatric patients with philadelphia chromosome positive chronic myeloid leukaemia (cml) in the chronic phase

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - efavirenz, quantity: 200 mg - tablet, film coated - excipient ingredients: carnauba wax; hyprolose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; sodium lauryl sulfate; lactose monohydrate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - stocrin is indicated for use in combination with other antiviral agents for the treatment of hiv-1 infection in adults and children (see clinical trials; use in children).

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - efavirenz, quantity: 600 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; sodium lauryl sulfate; hyprolose; lactose monohydrate; magnesium stearate; carnauba wax; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - storcrin is indicated for use in combination with other antiviral agents for the treatment of hiv-1 infection in adults and children. (see clinical trials; use in children)

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - clarithromycin 50 mg/ml;   - granules for oral suspension - 250 mg/5ml - active: clarithromycin 50 mg/ml   excipient: carbomer castor oil citric acid monohydrate hydrated silica hypromellose phthalate fruit mix flavour maltodextrin potassium sorbate povidone sucrose titanium dioxide xanthan gum - klacid suspension is indicated for treatment of infections caused by susceptible organisms. such infections include: ? upper respiratory infections (e.g. streptococcal pharyngitis). ? lower respiratory infections (e.g. bronchitis, pneumonia). ? acute otitis media. ? skin and skin structure infections (e.g. impetigo, folliculitis, cellulitis, abscesses). ? disseminated or localized mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare. localised infections due to mycobacterium chelonae, mycobacterium fortuitum or mycobacterium kansasii.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clarithromycin, quantity: 50 mg/ml - oral liquid, powder for - excipient ingredients: potassium sorbate; castor oil; titanium dioxide; hypromellose phthalate; maltodextrin; carbomer 934; citric acid; silicon dioxide; xanthan gum; sucrose; povidone; flavour - klacid (clarithromycin) is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis; 2. community acquired pneumonia due to chlamydia pneumoniae, mycoplasma pneumoniae, legionella pneumophila and streptococcus pneumoniae; 3. uncomplicated skin and skin structure infections due to staphylococcus aureus or streptococcus pyogenes; 4. disseminated or localised mycobacterial infections due to mycobacterium avium or mycobacterium intracellulare and skin and skin structure infections due to mycobacterium chelonae. clarithromycin should be used in combination with other antimycobacterial agents. 5. prevention of disseminated mycobacterium avium complex infection in hiv-infected adults with cd4 lymphocyte counts of < 75 cells/cubic mm. (see precautions) disseminated infection due to mycobacterium avium complex should be excluded by a negative blood culture prior to commencement of prophylaxis. 6. acute bacterial exacerbation of chronic bronchitis due to haemophilus influenzae, moraxella catarrhalis or streptococcus pneumoniae; 7. combination therapy for the treatment of peptic ulcer disease associated with helicobacter pylori infection. klacid (clarithromycin) is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below: 1. acute streptococcal pharyngitis and tonsillitis caused by streptococcus pyogenes; 2. community acquired pneumonia including infections due to chlamydia pneumoniae, mycoplasma pneumoniae and legionella pneumophila; 3. skin and skin structure infections (eg impetigo); 4. disseminated or localised infections due to mycobacterium avium or mycobacterium intracellulare in immunocompromised children, including those with hiv infection or aids. 5. acute otitis media. note: 1. penicillins are the drug of first choice in the treatment of acute otitis media. 2. penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present. 3. there is insufficient evidence of efficacy to support the use of klacid in acute bronchitis in young children. 4. the data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

abbott laboratories, united kingdom - clarithromycin - coated tablet - 500 mg